Literature DB >> 18199985

Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia.

L G Buchynska1, I P Nesina, E V Kashuba.   

Abstract

AIM: To study the expression of p53, MDM2, and p14 ARF in the highly, moderately and low differentiated endometrial adenocarcinomas, compared to hyperplasia.
MATERIAL AND METHODS: Surgical material and the scrapes of endometrial cancer, glandular and atypical hyperplasia patients. Expression of 53, MDM2 and p14 ARF was evaluated by immunohistochemical method using respective monoclonal antibodies.
RESULTS: High p53 expression level is accompanied by decreased level of MDM2 expression in endometrial cancers. On contrary, in endometrial hyperplasia, there was clear connection between the expression levels of p53 and MDM2. We hypothesize that the high p53 and low MDM2 levels in endometrial cancers could arise due to the inhibition of transcriptional activity of p53 by its binding to estrogen receptors.
CONCLUSION: High p53 expression level with low MDM2 and p14 ARF levels may be the characteristic features of low differentiated endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18199985

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  2 in total

1.  Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.

Authors:  Osamu Nunobiki; Masatsugu Ueda; Michiko Yamamoto; Eisaku Toji; Naomi Sato; Shinji Izuma; Yoshiaki Okamoto; Kiyo Torii; Sadamu Noda
Journal:  Hum Cell       Date:  2009-11       Impact factor: 4.174

2.  Mitochondrial ribosomal protein S18-2 is highly expressed in endometrial cancers along with free E2F1.

Authors:  Miriam Mints; Muhammad Mushtaq; Natalia Iurchenko; Larysa Kovalevska; Maria C Stip; Daria Budnikova; Sonia Andersson; Ludmila Polischuk; Lubov Buchynska; Elena Kashuba
Journal:  Oncotarget       Date:  2016-04-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.